Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
NCT02230982 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2019-02-08
Summary
To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF)
Conditions
Interventions
- DRUG
-
soft gelatin capsule
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Boehringer Ingelheim · Boehringer Ingelheim
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- Brazil
Study Locations
More Related Trials
-
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
NCT07080125 ·Status: ACTIVE_NOT_RECRUITING
-
Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)
NCT01134822 ·Status: COMPLETED
-
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
NCT05779007 ·Status: COMPLETED
-
Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
NCT02058602 ·Status: COMPLETED ·Phase: PHASE1
-
IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
NCT02803580 ·Status: COMPLETED
-
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
NCT05875532 ·Status: COMPLETED
-
Idiopathic Pulmonary Fibrosis Job Exposures Study
NCT03211507 ·Status: COMPLETED
-
Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis
NCT03104322 ·Status: COMPLETED ·Phase: NA
-
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
NCT00292552 ·Status: COMPLETED
-
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
NCT00373841 ·Status: RECRUITING
-
Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis
NCT02594059 ·Status: COMPLETED ·Phase: NA
-
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
NCT02315586 ·Status: COMPLETED
-
Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry
NCT00212511 ·Status: WITHDRAWN
-
Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis
NCT02151435 ·Status: COMPLETED
-
Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases
NCT00005317 ·Status: COMPLETED
-
Pulmonary Fibrosis Foundation Patient Registry
NCT02758808 ·Status: COMPLETED
-
Self-monitoring of Spirometry & Symptoms Via patientMpower App in Idiopathic Pulmonary Fibrosis
NCT03744598 ·Status: TERMINATED
-
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
NCT05895409 ·Status: RECRUITING
-
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
NCT00631475 ·Status: COMPLETED ·Phase: PHASE3
-
Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
NCT00258544 ·Status: ACTIVE_NOT_RECRUITING
-
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis
NCT01695408 ·Status: COMPLETED
-
Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis
NCT06629623 ·Status: ENROLLING_BY_INVITATION
-
Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
NCT05957198 ·Status: COMPLETED
-
Small Airways Disease Functional Assessment in Idiopathic Pulmonary Fibrosis (SWIFT-IPF)
NCT07312305 ·Status: RECRUITING
-
Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis
NCT02632123 ·Status: COMPLETED